메뉴 건너뛰기




Volumn 16, Issue 5, 2012, Pages 977-985

Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma

Author keywords

CA19 9; Early recurrence; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

EID: 84865330539     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1859-9     Document Type: Article
Times cited : (125)

References (42)
  • 3
    • 70249099504 scopus 로고    scopus 로고
    • A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
    • Sep 15
    • Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009 Sep 15;101(6):908-915.
    • (2009) Br J Cancer , vol.101 , Issue.6 , pp. 908-915
    • Ueno, H.1    Kosuge, T.2    Matsuyama, Y.3    Yamamoto, J.4    Nakao, A.5    Egawa, S.6    Doi, R.7    Monden, M.8    Hatori, T.9    Tanaka, M.10    Shimada, M.11    Kanemitsu, K.A.12
  • 4
    • 34250816847 scopus 로고    scopus 로고
    • A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
    • Jul
    • Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007 Jul;14(7):2088-2096.
    • (2007) Ann Surg Oncol , vol.14 , Issue.7 , pp. 2088-2096
    • Palmer, D.H.1    Stocken, D.D.2    Hewitt, H.3    Markham, C.E.4    Hassan, A.B.5    Johnson, P.J.6    Buckels, J.A.7    Bramhall, S.R.8
  • 7
    • 68249109951 scopus 로고    scopus 로고
    • Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer
    • Jul
    • Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009 Jul;250 (1):88-95.
    • (2009) Ann Surg , vol.250 , Issue.1 , pp. 88-95
    • Ohigashi, H.1    Ishikawa, O.2    Eguchi, H.3    Takahashi, H.4    Gotoh, K.5    Yamada, T.6    Yano, M.7    Nakaizumi, A.8    Uehara, H.9    Tomita, Y.10    Nishiyama, K.11
  • 10
    • 0033830039 scopus 로고    scopus 로고
    • Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice
    • Aug
    • Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000 Aug;26(5):474-479.
    • (2000) Eur J Surg Oncol , vol.26 , Issue.5 , pp. 474-479
    • Mann, D.V.1    Edwards, R.2    Ho, S.3    Lau, W.Y.4    Glazer, G.5
  • 11
    • 0042418394 scopus 로고    scopus 로고
    • Utility of tumor markers in determining resectability of pancreatic cancer
    • Sep, discussion 955-956
    • Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003 Sep;138(9):951-955; discussion 955-956.
    • (2003) Arch Surg , vol.138 , Issue.9 , pp. 951-955
    • Schlieman, M.G.1    Ho, H.S.2    Bold, R.J.3
  • 14
    • 16644368543 scopus 로고    scopus 로고
    • Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma
    • Jul
    • Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004 Jul;11(7):644-649.
    • (2004) Ann Surg Oncol , vol.11 , Issue.7 , pp. 644-649
    • Berger, A.C.1    Meszoely, I.M.2    Ross, E.A.3    Watson, J.C.4    Hoffman, J.P.5
  • 15
    • 33845631984 scopus 로고    scopus 로고
    • Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma
    • Dec
    • Shimada K, Sano T, Sakamoto Y, Kosuge T. Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol. 2006 Dec;13(12):1569-1578.
    • (2006) Ann Surg Oncol , vol.13 , Issue.12 , pp. 1569-1578
    • Shimada, K.1    Sano, T.2    Sakamoto, Y.3    Kosuge, T.4
  • 16
    • 33745552215 scopus 로고    scopus 로고
    • Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
    • Jun 20
    • Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006 Jun 20;24 (18):2897-2902.
    • (2006) J Clin Oncol , vol.24 , Issue.18 , pp. 2897-2902
    • Ferrone, C.R.1    Finkelstein, D.M.2    Thayer, S.P.3    Muzikansky, A.4    Fernandez-Delcastillo, C.5    Warshaw, A.L.6
  • 19
  • 20
    • 64249102059 scopus 로고    scopus 로고
    • Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer
    • May
    • Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009 May;16(5):1231-1240.
    • (2009) Ann Surg Oncol , vol.16 , Issue.5 , pp. 1231-1240
    • Waraya, M.1    Yamashita, K.2    Katagiri, H.3    Ishii, K.4    Takahashi, Y.5    Furuta, K.6    Watanabe, M.7
  • 21
    • 62349110974 scopus 로고    scopus 로고
    • Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: Prognostic value of the length of venous resection
    • 145
    • Kaneoka Y, Yamaguchi A, Isogai M. Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery. 2009 Apr; 145(4):417-425.
    • (2009) Surgery , Issue.4 , pp. 417-425
    • Kaneoka, Y.1    Yamaguchi, A.2    Isogai, M.3
  • 23
    • 0034009704 scopus 로고    scopus 로고
    • Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    • Mar
    • Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000 Mar;82(5):1013-1016.
    • (2000) Br J Cancer , vol.82 , Issue.5 , pp. 1013-1016
    • Halm, U.1    Schumann, T.2    Schiefke, I.3    Witzigmann, H.4    Mossner, J.5    Keim, V.6
  • 24
    • 0031594319 scopus 로고    scopus 로고
    • Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?
    • Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer. 1998;77(2):325-328.
    • (1998) Br J Cancer , vol.77 , Issue.2 , pp. 325-328
    • Gogas, H.1    Lofts, F.J.2    Evans, T.R.3    Daryanani, S.4    Mansi, J.L.5
  • 25
    • 0031952380 scopus 로고    scopus 로고
    • Prognostic value of CA 19-9 serum course in pancreatic cancer
    • Jan-Feb
    • Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998 Jan-Feb;45(19):253-259.
    • (1998) Hepatogastroenterology , vol.45 , Issue.19 , pp. 253-259
    • Safi, F.1    Schlosser, W.2    Falkenreck, S.3    Beger, H.G.4
  • 26
    • 77649159782 scopus 로고    scopus 로고
    • Serum CA19-9 alterations during preoperative gemcitabinebased chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival
    • Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M. Serum CA19-9 alterations during preoperative gemcitabinebased chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg. 2010 Mar;251(3):461-469.
    • (2010) Ann Surg , vol.251 , Issue.3 , pp. 461-469
    • Takahashi, H.1    Ohigashi, H.2    Ishikawa, O.3    Eguchi, H.4    Gotoh, K.5    Yamada, T.6    Nakaizumi, A.7    Uehara, H.8    Tomita, Y.9    Nishiyama, K.10    Yano, M.11
  • 27
    • 0031242791 scopus 로고    scopus 로고
    • Prediction of recurrence and survival by postresection CA 19-9 values in patients with adenocarcinoma of the pancreas
    • Oct-Nov
    • Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by postresection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997 Oct-Nov;4(7):551-556.
    • (1997) Ann Surg Oncol , vol.4 , Issue.7 , pp. 551-556
    • Montgomery, R.C.1    Hoffman, J.P.2    Riley, L.B.3    Rogatko, A.4    Ridge, J.A.5    Eisenberg, B.L.6
  • 31
    • 58049202340 scopus 로고    scopus 로고
    • Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704
    • Dec 20
    • Berger AC, Garcia M, Jr., Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, 3rd, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008 Dec 20;26 (36):5918-5922.
    • (2008) J Clin Oncol , vol.26 , Issue.36 , pp. 5918-5922
    • Berger, A.C.1    Garcia Jr., M.2    Hoffman, J.P.3    Regine, W.F.4    Abrams, R.A.5    Safran, H.6    Konski, A.7    Benson III, A.B.8    Macdonald, J.9    Willett, C.G.10
  • 33
    • 0033504196 scopus 로고    scopus 로고
    • Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy
    • Aug
    • Povoski SP, Karpeh MS, Jr., Conlon KC, Blumgart LH, Brennan MF. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg. 1999 Aug;230(2):131-142.
    • (1999) Ann Surg , vol.230 , Issue.2 , pp. 131-142
    • Povoski, S.P.1    Karpeh Jr., M.S.2    Conlon, K.C.3    Blumgart, L.H.4    Brennan, M.F.5
  • 34
    • 0034982634 scopus 로고    scopus 로고
    • The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy
    • Jun
    • Sewnath ME, Birjmohun RS, Rauws EA, Huibregtse K, Obertop H, Gouma DJ. The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy. J Am Coll Surg. 2001 Jun;192(6):726-734.
    • (2001) J Am Coll Surg , vol.192 , Issue.6 , pp. 726-734
    • Sewnath, M.E.1    Birjmohun, R.S.2    Rauws, E.A.3    Huibregtse, K.4    Obertop, H.5    Gouma, D.J.6
  • 35
    • 34247620806 scopus 로고    scopus 로고
    • The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer
    • Jun 1
    • Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007 Jun 1;140(1):31-35.
    • (2007) J Surg Res , vol.140 , Issue.1 , pp. 31-35
    • Kang, C.M.1    Kim, J.Y.2    Choi, G.H.3    Kim, K.S.4    Choi, J.S.5    Lee, W.J.6    Kim, B.R.7
  • 38
  • 39
    • 45849137113 scopus 로고    scopus 로고
    • Value of Multidetector-row Computed Tomography in Diagnosis of Portal Vein Invasion by Perihilar Cholangiocarcinoma
    • Jul
    • Sugiura T, Nishio H, Nagino M, Senda Y, Ebata T, Yokoyama Y, Igami T, Oda K, Nimura Y. Value of Multidetector-row Computed Tomography in Diagnosis of Portal Vein Invasion by Perihilar Cholangiocarcinoma. World J Surg. 2008 Jul;32(7):1478-1484.
    • (2008) World J Surg , vol.32 , Issue.7 , pp. 1478-1484
    • Sugiura, T.1    Nishio, H.2    Nagino, M.3    Senda, Y.4    Ebata, T.5    Yokoyama, Y.6    Igami, T.7    Oda, K.8    Nimura, Y.9
  • 40
    • 67349262392 scopus 로고    scopus 로고
    • Value of multidetector row CT in the assessment of longitudinal extension of cholangiocarcinoma: Correlation between MDCT and microscopic findings
    • Jul
    • Senda Y, Nishio H, Oda K, Yokoyama Y, Ebata T, Igami T, Sugiura T, Shimoyama Y, Nimura Y, Nagino M. Value of multidetector row CT in the assessment of longitudinal extension of cholangiocarcinoma: correlation between MDCT and microscopic findings. World J Surg. 2009 Jul;33(7):1459-1467.
    • (2009) World J Surg , vol.33 , Issue.7 , pp. 1459-1467
    • Senda, Y.1    Nishio, H.2    Oda, K.3    Yokoyama, Y.4    Ebata, T.5    Igami, T.6    Sugiura, T.7    Shimoyama, Y.8    Nimura, Y.9    Nagino, M.10
  • 41
    • 38549096291 scopus 로고    scopus 로고
    • Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer
    • Jan
    • Noji T, Kondo S, Hirano S, Tanaka E, Suzuki O, Shichinohe T. Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer. Br J Surg. 2008 Jan;95(1):92-96.
    • (2008) Br J Surg , vol.95 , Issue.1 , pp. 92-96
    • Noji, T.1    Kondo, S.2    Hirano, S.3    Tanaka, E.4    Suzuki, O.5    Shichinohe, T.6
  • 42
    • 0023637227 scopus 로고
    • Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer
    • Oct 15
    • Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15;47 (20):5501-5503.
    • (1987) Cancer Res , vol.47 , Issue.20 , pp. 5501-5503
    • Tempero, M.A.1    Uchida, E.2    Takasaki, H.3    Burnett, D.A.4    Steplewski, Z.5    Pour, P.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.